Press Release

xrmta Vimta Labs Limited Registered Office 142, IDA Phase II, Cherlapally Hyderabad-500 051, Telangana, India T: ~91 4027264141 F : +91 4027263657 Driven byQuality. Inspired byScience. VLL\SE\034\2026 27 Date: 20.07.2026 B S E Limited, National Stock Exchange of India Limited, P Towers, Dalal Street, “Exchange Plaza”, Bandra, Kurla Complex, Mumbai 400001. Bandra (E), Mumbai 400051. Scrip Code: 524394 Trading Symbol: VIMTALABS Dear Sir/Madam, Sub Press Release Unaudited Financial Results 30”June 2026. With reference to the subject cited above and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release regarding the announcement ofthe Unaudited Financial Results for the first quarter ended June 2026. This is for your mformation and records. Thankingyou, ForVIMTA LABS LIMITED Sujani Vasireddi Company Secretary and Compliance Officer End: as above. Plot No. 5, LifeSciences Facility, NeovantageScience &Technology Park Private Limited, Shamirpet, GenomeValley, Turkapally Medchal-Malkajgiri, Hyderabad-500101,Telangana, India. T : +91 4067404040 E: mdoffice@vimta.com URL : www.vimta.com CIN : L24110TG1990PL0011977 PRESS RELEASE For Immediate dissemination Vimta Labs Limited Q1 FY27 Results Q1 FY27 Total Income at Rs. 1,129 Mn, up 13.7% YoY EBITDA margins at 36.4%; PAT margin at 18.6% Hyderabad, July 20, 2026: Vimta Labs Limited (VIMTA) (BSE: 524394, NSE: VIMTALABS), India’s leading Contract Research and Testing Organisation, has announced its financial results for the quarter ended June 30, 2026. Financial Results – Q1 FY27: Particulars (₹ Mn) Q1 FY27 Q4 FY26 QoQ(%) Q1 FY26 YoY (%) Total Income 1,129 1,120 0.8% 993 13.7% EBITDA (including other income) 411 421 -2.4% 354 16.0% EBITDA Margin 36.4% 37.6% 35.7% PAT 210 211 -0.3% 189 11.4% PAT Margin 18.6% 18.9% 19.0% Basic EPS 4.7 4.7 -0.5% 4.2 11.0% Commenting on the results, Ms. Harita Vasireddi, Managing Director, Vimta Labs Limited, said: "Vimta Labs delivered another strong quarter, with total income of ₹1,129 Mn, up 13.7% YoY. Our Pharmaceutical Research and Testing Services business recorded healthy traction during the quarter. While ongoing global uncertainties continued to impact the Food Testing division, the business is progressively offsetting these headwinds through deeper domestic market penetration and improved traction in local opportunities. The quarter’s performance underscores the resilience of our operating model and the strength of our diversified service portfolio. During the quarter, we successfully completed a regulatory audit from Ukraine, reaffirming our continued focus on quality and compliance. We also commenced operations in Biologics contract research and development services (CRADS), marking an important addition to our capabilities. Looking ahead, we remain optimistic about industry prospects and evolving business opportunities, supported by our strong capabilities, customer-centric approach, and expanding service portfolio." Key Result Highlights for the Q1 FY27: Q1 FY27  Total Income for Q1 FY27 was at ₹1,129 Mn  EBITDA for Q1 FY27 was ₹411 Mn; EBITDA margin was at 36.4%  PBT for Q1 FY27 was at ₹283 Mn  Q1 FY27 PAT was at ₹210 Mn; PAT margin was at 18.6%  Basic EPS in Q1 FY27 was ₹4.7 PRESS RELEASE For Immediate dissemination ABOUT VIMTA LABS LIMITED: Founded in 1984 with headquarters in Hyderabad, India, VIMTA LABS LTD., is a leading contract research and testing organization, providing food, agri, bio/pharmaceutical, medical device, speciality chemical, and electronics companies an integrated scientific, technical, and regulatory expertise to support all stages of product development and manufacturing process. Vimta also provides environmental assessments and testing services. CAUTIONARY STATEMENT: This press release may contain certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Vimta Labs Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent. For details, please contact: Investor Relations at Vimta Labs Registered Office Siva Kambhampati Plot Number 142, IDA Phase 2, Cherlapally, Hyderabad (Chief Financial Officer) Telangana, India. 500051 Siva.Kambhampati@Vimta.com CIN: L24110TG1990PLC011977 Ernst & Young ISIN: INE579C01029 Siddesh Chawan NSE Code: VIMTALABS Siddesh.Chawan@in.ey.com BSE CODE: 524394 Advait Bhadekar Website: www.vimta.com Advait.bhadekar@in.ey.com